NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

Final Stakeholder list

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Merck (avelumab) Patient/carer groups • Action Kidney Cancer • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • Cancer 52 • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Kidney Cancer UK • Kidney Care UK • Kidney Patient Involvement Network • Kidney Research UK • Macmillan Cancer Support • Maggie's Centres • Marie Curie • National Kidney Federation • Pelican Cancer Foundation • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Healthcare professional groups • Association of Cancer Physicians • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Kidney Wales • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Other relevant companies • Pfizer (axitinib) Comparator companies • Accord-UK (sunitinib) • Bristol Myers Squibb Pharmaceuticals (ipilimumab, nivolumab) • Dr Reddy's Laboratories (sunitinib) • Eisai (lenvatinib) • Eusa Pharma (tivozanib) • Ipsen (cabozantinib)

Provisional Consultees	**Provisional Commentators (no right to submit or appeal)**
Association • British Psychosocial Oncology Society • British Society of Urogenital Radiology • British Uro-oncology Group • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • Society for DGH Nephrologists • UK Clinical Pharmacy Association • UK Kidney Association • UK Oncology Nursing Society • UK Renal Pharmacy Group • Urology Foundation <u>Others</u> • Department of Health and Social Care • NHS England	• Merck Sharp & Dohme (UK) (pembrolizumab) • MSN laboratories (sunitinib) • Novartis (pazopanib) • Pfizer (sunitinib) • Piramal Critical Care (sunitinib) • Sandoz (sunitinib) • Teva UK (sunitinib) • Viatris UK Healthcare (sunitinib) • Zentiva (sunitinib) <u>Relevant research groups</u> • Cochrane Kidney and Transplant Group • Cochrane UK • Cochrane Urology • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.

